MetLife
MET
$94.42
-0.79%
MetLife, Inc. is one of the largest global life insurers, offering a diversified portfolio of life insurance, annuities, employee benefits, and retirement solutions across six operating segments, including Group Benefits, Retirement and Income Solutions, Asia, Latin America, EMEA, and MetLife Holdings. With a market capitalization of approximately $62.5 billion and over 46,000 employees, the company holds leading market positions in the U.S., Japan, Mexico, and Chile, distinguishing itself as a top-tier player in the insurance industry. The current investor narrative centers on the company's robust earnings growth, driven by favorable underwriting results and strong performance in its U.S. and Asia segments, alongside a strategic focus on capital return through dividends and share buybacks. Additionally, the stock has outperformed the broader market over the past year, reflecting confidence in its ability to navigate interest rate dynamics and maintain profitability in a competitive landscape.…
MET
MetLife
$94.42
Investment Opinion: Should I buy MET Today?
Based on the analysis, MetLife is rated a Buy. The stock offers a compelling risk/reward with a forward PE of 8.84x, a dividend yield of 3.24%, and a consensus analyst target price of $105.06, implying 8.86% upside. The company's strong free cash flow of $16.53 billion supports capital returns, and its diversified business segments provide stability.
Sign up to view all
MET 12-Month Price Forecast
The AI assessment is bullish on MetLife, given the attractive valuation and strong cash flow generation. The forward PE suggests significant earnings growth, and the company's diversified business provides stability. However, the medium confidence reflects uncertainties around margin trends and interest rate movements. If earnings growth materializes as expected, the stock could appreciate; otherwise, it may face headwinds. Key factors to monitor include quarterly earnings, margin trends, and interest rate policy.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on MetLife's 12-month outlook, with a consensus price target around $105.06 and implied upside of +11.3% versus the current price.
Average Target
$105.06
0 analysts
Implied Upside
+11.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $119
Analyst target range
MetLife is covered by 16 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 1.94 (where 1 is strong buy and 5 is sell). The average target price is $105.06, implying an upside of approximately 8.86% from the current price of $96.51. The analyst sentiment is bullish, with no sell ratings and a majority of buy or overweight ratings, reflecting confidence in the company's growth prospects. The target price range spans from $84.00 to $119.00, indicating a wide dispersion in expectations. The high target of $119.00 suggests that some analysts see significant upside potential, possibly driven by strong earnings growth and favorable market conditions, while the low target of $84.00 implies downside risks such as margin compression or competitive pressures. Recent ratings from firms like Keefe, Bruyette & Woods, Jefferies, and UBS have been positive, with actions such as 'Outperform' and 'Buy', reinforcing the bullish outlook.
Bulls vs Bears: MET Investment Factors
MetLife presents a compelling bull case with strong earnings growth expectations, attractive valuation metrics, and robust free cash flow. The forward PE of 8.84x suggests significant upside if earnings meet analyst estimates, and the stock has outperformed the market with a 1-year return of 19.44%. However, margin compression and interest rate sensitivity pose risks that could undermine the thesis. The bear case is weaker, as the company's diversified business and solid balance sheet mitigate most concerns. The most important tension is whether the expected earnings growth will materialize, as the stock's valuation hinges on this. If EPS reaches $13.50, the stock is undervalued; if not, it could be overvalued. Currently, the bull case has stronger evidence, given the positive analyst sentiment and strong cash flow generation.
Bullish
- Strong Earnings Growth Expected: The forward PE of 8.84x is significantly lower than the trailing PE of 16.45x, implying the market expects a sharp increase in earnings. Analysts estimate EPS of $13.50 for the next fiscal year, up from the current trailing EPS of $5.87, indicating robust growth prospects.
- Solid Revenue Growth: Q1 2026 revenue grew 4.44% year-over-year to $19.074 billion, and the company has consistently generated revenue above $17 billion in recent quarters. This growth is supported by strong performance in U.S. and Asia segments, which contribute to a diversified revenue base.
- Attractive Valuation vs. Peers: With a PS ratio of 0.68x and a forward PE of 8.84x, MetLife trades at a discount to the broader market and its own historical averages. The trailing PE of 16.45x is near the lower end of its 5-year range, suggesting the stock is reasonably priced relative to its earnings power.
- Strong Free Cash Flow: MetLife generated $16.53 billion in free cash flow over the trailing twelve months, providing ample liquidity for dividends and share buybacks. This supports a dividend yield of 3.24% and a payout ratio of 50.4%, indicating a sustainable capital return program.
Bearish
- Margin Compression Risk: Net margin declined to 6.21% in Q1 2026 from 8.89% in Q4 2024, and operating margin is only 6.05%. This suggests that rising costs or competitive pressures could erode profitability, potentially impacting earnings growth.
- High Valuation on Trailing Earnings: The trailing PE of 16.45x is elevated compared to the forward PE, and the stock trades near its 52-week high of $100.93. If earnings growth fails to materialize, the stock could face multiple compression, leading to a price decline.
- Interest Rate Sensitivity: As a life insurer, MetLife's investment income and product spreads are sensitive to interest rate changes. A prolonged low-rate environment could compress margins, while rapid rate hikes could impact bond portfolio values, affecting book value and earnings.
- Geopolitical and Regulatory Exposure: With significant operations in Asia, Latin America, and EMEA, MetLife faces regulatory and geopolitical risks. Changes in local regulations or economic instability in key markets like Japan or Mexico could disrupt earnings.
MET Technical Analysis
MetLife's stock is in a strong uptrend, with a 1-year price change of +19.44% and a 6-month change of +33.91%, indicating sustained bullish momentum. The current price of $96.51 sits near the upper end of its 52-week range, at approximately 95.6% of the range (calculated as (96.51 - 67.33) / (100.93 - 67.33) * 100), suggesting the stock is trading close to its highs, which reflects positive investor sentiment but also potential overextension. The stock's beta of 0.763 indicates it is less volatile than the broader market, providing a defensive characteristic that may appeal to risk-averse investors.
Beta
0.76
0.76x market volatility
Max Drawdown
-18.3%
Largest decline past year
52-Week Range
$67-$101
Price range past year
Annual Return
+16.1%
Cumulative gain past year
| Period | MET Return | S&P 500 |
|---|---|---|
| 1m | -1.8% | +2.0% |
| 3m | +16.6% | +1.0% |
| 6m | +29.4% | +11.8% |
| 1y | +16.1% | +18.1% |
| ytd | +17.6% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MET Fundamental Analysis
MetLife's revenue has shown a mixed but generally positive trajectory, with the most recent quarter (Q1 2026) reporting revenue of $19.074 billion, a 4.44% year-over-year increase, though this follows a strong Q4 2025 with revenue of $23.814 billion. The company's net income has been volatile, with Q1 2026 net income of $1.185 billion, up from $809 million in Q4 2025, but down from $1.271 billion in Q4 2024. Gross margin improved to 37.24% in Q1 2026 from 30.53% in Q4 2025, indicating better cost management. The company's profitability is solid, with a net margin of 6.21% in Q1 2026, though this is lower than the 8.89% in Q4 2024, reflecting some margin compression. MetLife's balance sheet remains strong, with a debt-to-equity ratio of 0.71, and it generated robust free cash flow of $16.53 billion over the trailing twelve months, providing ample liquidity for dividends and buybacks. The current ratio of 0.65 is low, but this is typical for insurance companies due to their business model, and the company's ROE of 11.90% indicates efficient use of equity.
Quarterly Revenue
$19.1B
2026-03
Revenue YoY Growth
+4.4%
YoY Comparison
Gross Margin
37.2%
Latest Quarter
Free Cash Flow
$16.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MET Overvalued?
Given that MetLife is profitable, the PE ratio is the primary valuation metric. The trailing PE is 16.45x, while the forward PE is 8.84x, indicating that the market expects significant earnings growth, as the forward multiple is substantially lower. This gap suggests that analysts anticipate a sharp increase in earnings, likely due to improved underwriting and investment income. Compared to the industry average, MetLife's forward PE of 8.84x is at a discount to the broader market, but the company's PS ratio of 0.68x is below the sector average, suggesting the stock is undervalued relative to sales. Historically, MetLife's PE has ranged from as low as 3.89x in Q2 2021 to as high as 795.88x in Q1 2023, with the current trailing PE of 16.45x near the lower end of its historical band, indicating that the stock is trading at a reasonable valuation relative to its own history.
PE
16.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks include margin compression, as net margin fell to 6.21% in Q1 2026 from 8.89% in Q4 2024, and operating margin is only 6.05%. The company's debt-to-equity ratio of 0.71 is manageable, but the low current ratio of 0.65 could indicate liquidity constraints in a stress scenario. Additionally, revenue growth has been modest at 4.44% YoY, and net income is volatile, with Q1 2026 net income of $1.185 billion down from $1.271 billion in Q4 2024. These factors could pressure earnings if not managed effectively.